Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$22.33
Change (%) Stock is Down 0.08 (0.36%)
Volume195,053
Data as of 11/28/14 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
11/19/14OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
- Data Bode Well for Success of Ongoing Phase 2 Trial in Thrombotic Microangiopathies - SEATTLE, Nov. 19, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs a... 
 Printer Friendly Version
11/10/14Omeros Corporation Reports Third Quarter 2014 Financial Results
-- Omidria™ U.S. Commercial Launch Planned for Early 2015 -- SEATTLE, Nov. 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2... 
 Printer Friendly Version
11/06/14Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
-- Lectin Pathway Identified as Key Contributor to Stroke Sequelae -- SEATTLE, Nov. 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key pa... 
 Printer Friendly Version
11/04/14Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
SEATTLE, Nov. 4, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2014 financial results for the period ended September 30, 2014, on Monday, November 10, 2014, after market cl... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2013 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.